⚔️ Head-to-head
Cagrilintide vs Retatrutide
Pep lines up the two side by side — verdict, mechanism, and the dimensions that actually differ — so you can see where each one wins.
By MrPepTalks Editorial · Updated 2026-07-08
Cagrilintide
AM833 · Cagrilintide
promisingRetatrutide
LY3437943
promising🏆 Wins on evidence maturity
Cagrilintide
Dimension
Retatrutide
An amylin analog: a long-acting molecule studied for action on amylin and calcitonin receptors, a pathway tied to satiety and appetite signalling. It works through a different system than the incretin drugs and is most often paired with a GLP-1 partner rather than used alone.
Receptor mechanism
A triple-agonist studied for action at three receptors at once: GLP-1, GIP, and glucagon. The added glucagon arm is the headline difference, and it is designed as a standalone next-step molecule rather than a combination partner.
Most commonly researched as one half of a combination — the CagriSema pairing with semaglutide — where the amylin arm is explored for how it complements a GLP-1 agonist. Its standalone human record is thinner than its combination record.
How it is typically studied
Commonly researched on its own for body-weight reduction and metabolic markers in obesity and type-2-diabetes trials. It is studied as a single molecule, which makes its individual signal easier to read.
Commonly researched for appetite regulation and body-weight reduction, most visibly in combination trials. People report interest because the amylin pathway is a different lever than the incretin drugs everyone already knows.
What it is commonly researched for
Commonly researched for body-weight reduction and glucose control. Early trial readouts drew wide attention and are the reason it is often described as posting some of the largest reported figures in the class, though the human record is still growing.
Earlier-stage as a solo agent: most of the stronger human data comes from combination studies, so the standalone picture is less complete. Signals are emerging rather than settled.
Evidence maturity
Also investigational, but with a growing set of dedicated phase-2 readouts and reported phase-3 work as a single molecule. Its standalone human dataset is further along than cagrilintide's solo record, though neither is a finished long-term story.
🏆 winner
The most reported effects in trials are gastrointestinal — nausea and reduced appetite — broadly consistent with molecules that dampen hunger signalling. As a newer agent, its long-term profile is still thinly characterized.
Reported side-effect profile
The most reported effects are also gastrointestinal — nausea, vomiting, and diarrhea — in the same broad family as other incretin molecules. Because more people have been studied on it as a solo agent, its profile is somewhat better described, but still not long-term.
Research-grade cagrilintide is investigational and is not FDA-approved. It has no branded prescription form of its own and is intended for laboratory research use only.
Regulatory status
Research-grade retatrutide is likewise investigational and is not FDA-approved. It has no branded prescription form on the market and is intended for laboratory research use only.
No prescription version exists, so anything sold as research-grade cagrilintide carries the usual gray-market unknowns: contamination, endotoxins, and identity that may not match the label. The honest read is early and combination-focused.
Availability and honest bottom line
No prescription version exists either, so research-grade retatrutide carries the same gray-market unknowns. The honest read is promising-but-unsettled as a standalone. The takeaway: two investigational molecules on different pathways and different development paths — neither has crossed into approved use.
Cagrilintide data sheetThe terse reference: facts, forms, and Pep's verdict.Retatrutide data sheetThe terse reference: facts, forms, and Pep's verdict.
Send it to me →
No spam. Compliant with CAN-SPAM (US), CASL (Canada) & GDPR (EU) · one-click unsubscribe. See our Privacy Policy.